TOP > 外国特許検索 > RELIEF FROM OSTEOARTHRITIS PAIN BY TARGETING MICRORNA-21

RELIEF FROM OSTEOARTHRITIS PAIN BY TARGETING MICRORNA-21 NEW

外国特許コード F190009983
整理番号 (S2018-0473-N0)
掲載日 2019年10月28日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP009867
国際公開番号 WO 2019176901
国際出願日 平成31年3月12日(2019.3.12)
国際公開日 令和元年9月19日(2019.9.19)
優先権データ
  • 特願2018-044744 (2018.3.12) JP
発明の名称 (英語) RELIEF FROM OSTEOARTHRITIS PAIN BY TARGETING MICRORNA-21 NEW
発明の概要(英語) An objective of the present invention is to elucidate the cause of pain in osteoarthritis and to contribute to the development of a therapeutic agent for alleviating the pain of osteoarthritis. An agent for relieving pain from osteoarthritis, the agent including an MiR-21 inhibitor as the active ingredient, or an agent for relieving pain from osteoarthritis, the agent including a TLR antagonist as the active ingredient.
従来技術、競合技術の概要(英語) BACKGROUND ART
Osteoarthritis (osteoarthritis: OA) is a high prevalence, and has the chronic disease. Heisei 25th Life of the population based care insurance perspective view of the support according to the investigation of care is required at 1 the main cause of the pain of a joint, the joint of the subjective symptom of the population in the upper limb and the pain. Osteoarthritis drug therapies for pain alleviation of non-steroidal anti-inflammatory drug or acetaminophen, opioid or the like is used, the effectiveness is insufficient due to the artificial joint replacement in the case where a therapy such as surgery on the increase. Of an existing drug therapy may have many adverse effects of acute, chronic for deleterious effect associated with the use, the development of new analgesic has been desired. In the cause of the pain of osteoarthritis is still not clear, for the development of new analgesic osteoarthritis in the cause of the pain is required.
In recent years, a variety of diseases in pain associated with the importance of the microRNA has been reported that, in the pain of osteoarthritis of the little report microRNA function.
In a recent study, extracellular microRNA Toll-like receptor cell in the 7 after binding (Toll like receptor; TLR), a variety of physiological functions have been reported. TLR7 Is, the sensation of pain associated with the function of the spinal cord dorsal root ganglia (DRG) smaller neuronal (sensory) and expressed, and pain involved in the control are known.
Patent Document 1 is (US 9267139 B2), as an example of a musculo-skeletal diseases illustrated in osteoarthritis, as a treatment method, attention is paid to the miRNA, or reduces the expression of miR-29b-1 discloses a method for controlling. However, 29 years-41 years of age from the patient's bone marrow mesenchymal stem cells (BMSCs) 64 of the age of-73 years as compared to the change in microRNA BMSCs remains being examined, and possibly also adaptive disease is likely to be as long as the relationship between the disease and is not intended to be written, an agent involved in the expression of microRNA (microRNA inhibitors and the like) not to mention whether or not to control pain, an agent involved in the expression of microRNA expression of the microRNA to the actual change is not to confirm. Further, the fact that the treatment of osteoarthritis, or whether the treatment of pain treatment of cartilage degeneration is not expressly recited.
Patent Document 2 (WO 2013/151058) is, by controlling the expression of the miR-140, osteoarthritis or degenerative disc disease of the cartilage such as the method for treating a disease is disclosed, this is, the pain of osteoarthritis therapeutic agent but, by controlling the differentiation of cartilage, in the treatment of osteoarthritis. Cartilage degeneration does not correlate with the number of reports that the pain is present, although the present invention are different.
Patent Document 3 (JP Patent Application 2012-504651) is, by inhibiting the activity of TLR3, and a method for treating inflammatory conditions, one aspect of the osteoarthritis are listed, only, but only listed.
Patent Document 4 (JP Patent Application 2011-502170) is, the disease treatment or prevention of osteoarthritis TLR4 antagonist for use. TLR4 Is activated, due to an increase in the release of inflammatory cytokines, osteoarthritis inflammatory response by the onset of the disease that is linked to the present invention, TLR7, 8, 9 is not of interest.
Patent Document 5 (JP Patent Application 2016-512561) is, in order to reduce the pain and TLR4 antagonist is noted that the present invention. As a disease, and osteoarthritis However, TLR7, 8, 9 is not of interest. In addition, lower back pain, pain in the vulva, trigeminal neuralgia, such as migraine test is performed for, for osteoarthritis, no test is not performed.
TLR antagonists it is needless to say, the type of receptor is different from that of the site of action, in a completely different.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NIPPON MEDICAL SCHOOL FOUNDATION
  • 発明者(英語)
  • HOSHIKAWA Naoya
  • SAKAI Atsushi
  • SUZUKI Hidenori
  • TAKAI Shinro
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close